Biotech News

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

Pulse Biosciences (PLSE)Pulse BiosciencesCompany update

164 evaluable patients enrolled across 15 clinical sites HAYWARD, Calif. --(BUSINESS WIRE)--Oct. 7, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that its NANOPULSE-AF

Related news

PLSEPulse Biosciences2026-10-14 11:00 EST

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

ICUSeaStar Medical2026-11-03 13:21 EST

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

VTAKCatheter Precision2026-11-02 13:00 EST

Catheter Precision Announces New FDA 510(k) Clearance for its VIVO System, Enabling Use in a Broader Patient Population

ICCMIceCure Medical2026-10-27 12:33 EST

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

FEMYFEMASYS2026-10-14 13:00 EST

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

ICUSeaStar Medical2026-10-07 12:16 EST

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

LUNGPulmonx2026-11-17 12:10 EST

Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System

MMSIMerit Medical2026-10-29 20:03 EST

Merit Medical Acquires Solo Pace, Inc., Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology

Pulse Biosciences

Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac...

Recent company news

Stock data

Close
44.41 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States